Comparison of Clinical Outcomes Between Ticagrelor and Clopidogrel in Acute Coronary Syndrome: A Comprehensive Meta-Analysis.

ABSTRACT:

Background

Ticagrelor is currently recommended for patients with the acute coronary syndrome (ACS). However, recent studies have yielded controversial results.

Objective

To compare the clinical outcomes between ticagrelor and clopidogrel in patients with ACS.

Methods

Three electronic databases were queried until April 25, 2021. We defined major adverse cardiovascular events (MACEs) as the primary efficacy endpoint. The secondary efficacy endpoints included stroke, stent thrombosis, cardiovascular death, all-cause death, and myocardial infarction. The safety endpoints were (major and minor) bleeding. Odds ratios (ORs) and 95% CIs were calculated to represent the estimated effect sizes.

Results

A total of 270,937 patients with ACS from 10 clinical trials and 18 o

SUBMITTER: Sun M 

PROVIDER: S-EPMC8829718 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature